Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 10 04:00PM ET
11.58
Dollar change
+0.35
Percentage change
3.12
%
Index- P/E- EPS (ttm)-18.96 Insider Own38.80% Shs Outstand6.50M Perf Week2.48%
Market Cap75.27M Forward P/E- EPS next Y-12.51 Insider Trans0.00% Shs Float3.98M Perf Month4.70%
Income-123.32M PEG- EPS next Q-2.65 Inst Own27.13% Short Float0.19% Perf Quarter-0.17%
Sales0.00M P/S- EPS this Y-15.09% Inst Trans0.92% Short Ratio0.53 Perf Half Y54.56%
Book/sh31.65 P/B0.37 EPS next Y-7.17% ROA-33.63% Short Interest0.01M Perf Year-13.09%
Cash/sh23.66 P/C0.49 EPS next 5Y- ROE-47.71% 52W Range6.07 - 13.70 Perf YTD51.97%
Dividend Est.- P/FCF- EPS past 5Y-120.38% ROI-42.53% 52W High-15.47% Beta1.20
Dividend TTM- Quick Ratio14.19 Sales past 5Y-25.00% Gross Margin- 52W Low90.77% ATR (14)0.52
Dividend Ex-Date- Current Ratio14.19 EPS Y/Y TTM30.37% Oper. Margin0.00% RSI (14)60.38 Volatility5.98% 4.19%
Employees49 Debt/Eq0.42 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price90.00
Option/ShortNo / Yes LT Debt/Eq0.41 EPS Q/Q57.42% Payout- Rel Volume3.92 Prev Close11.23
Sales Surprise- EPS Surprise-7.17% Sales Q/Q- EarningsMay 10 BMO Avg Volume14.00K Price11.58
SMA207.08% SMA502.77% SMA20022.79% Trades Volume54,820 Change3.12%
Date Action Analyst Rating Change Price Target Change
Apr-12-24Downgrade Jefferies Buy → Hold $5 → $11
Nov-01-22Downgrade Truist Buy → Hold $16 → $6
Nov-01-22Downgrade Cowen Outperform → Market Perform
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
May-10-24 01:54PM
07:00AM
Mar-27-24 12:00PM
Mar-21-24 10:52PM
05:00PM
12:28PM Loading…
Jan-18-24 12:28PM
Jan-16-24 08:00AM
Dec-13-23 10:52AM
10:51AM
Dec-05-23 05:00PM
Nov-13-23 05:00PM
Nov-06-23 07:00AM
Aug-31-23 09:35AM
Aug-14-23 07:00AM
Jun-26-23 04:38PM
07:00AM Loading…
May-11-23 07:00AM
Mar-31-23 07:00AM
Mar-22-23 07:57AM
Feb-17-23 07:04AM
Jan-31-23 05:00PM
Jan-09-23 12:30PM
07:00AM
Dec-13-22 09:35AM
Dec-09-22 09:35AM
Dec-08-22 11:04AM
07:00AM
Nov-14-22 04:07PM
Nov-08-22 07:00AM
Oct-31-22 10:40AM
08:52AM
07:00AM Loading…
07:00AM
Oct-18-22 07:00AM
Sep-19-22 07:20AM
Sep-09-22 07:00AM
Sep-06-22 07:00AM
Aug-12-22 07:00AM
Jul-12-22 08:21AM
Jul-11-22 05:28PM
May-27-22 07:00AM
May-18-22 07:00AM
May-16-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 07:00AM
Nov-15-21 07:00AM
07:00AM
Nov-10-21 11:28AM
Nov-08-21 08:05AM
Sep-16-21 07:00AM
Sep-15-21 04:27PM
Sep-13-21 07:00AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-19-21 02:34PM
Jun-21-21 10:06AM
Jun-01-21 07:00AM
May-13-21 07:00AM
Apr-29-21 08:45AM
Apr-27-21 07:00AM
Apr-12-21 07:18AM
Mar-23-21 05:00PM
Mar-19-21 04:25PM
Mar-18-21 08:26PM
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.